GB9501178D0 - Guanine derivative - Google Patents

Guanine derivative

Info

Publication number
GB9501178D0
GB9501178D0 GBGB9501178.9A GB9501178A GB9501178D0 GB 9501178 D0 GB9501178 D0 GB 9501178D0 GB 9501178 A GB9501178 A GB 9501178A GB 9501178 D0 GB9501178 D0 GB 9501178D0
Authority
GB
United Kingdom
Prior art keywords
guanine derivative
guanine
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB9501178.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB9501178(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Priority to GBGB9501178.9A priority Critical patent/GB9501178D0/en
Publication of GB9501178D0 publication Critical patent/GB9501178D0/en
Priority to ARP960101082A priority patent/AR002270A1/es
Priority to CN96192662A priority patent/CN1049893C/zh
Priority to EA199700124A priority patent/EA000364B1/ru
Priority to ZA96449A priority patent/ZA96449B/xx
Priority to AT96900631T priority patent/ATE302777T1/de
Priority to BR9606768A priority patent/BR9606768A/pt
Priority to UA97084268A priority patent/UA46001C2/uk
Priority to SK965-97A priority patent/SK285329B6/sk
Priority to AU44539/96A priority patent/AU702794B2/en
Priority to SI9630717T priority patent/SI0804436T1/sl
Priority to HU9801836A priority patent/HU222993B1/hu
Priority to ES96900631T priority patent/ES2248806T3/es
Priority to IN102MA1996 priority patent/IN182468B/en
Priority to CZ0229497A priority patent/CZ297065B6/cs
Priority to TR97/00656T priority patent/TR199700656T1/xx
Priority to YU3396A priority patent/RS49518B/sr
Priority to EE9700175A priority patent/EE03528B1/xx
Priority to DK96900631T priority patent/DK0804436T3/da
Priority to CA002210799A priority patent/CA2210799C/en
Priority to PCT/GB1996/000117 priority patent/WO1996022291A1/en
Priority to JP52213196A priority patent/JP3176633B2/ja
Priority to PL96321326A priority patent/PL182175B1/pl
Priority to HR960024A priority patent/HRP960024B1/xx
Priority to KR1019970704916A priority patent/KR100376074B1/ko
Priority to EP96900631A priority patent/EP0804436B1/en
Priority to DE69635106T priority patent/DE69635106T2/de
Priority to APAP/P/1997/001058A priority patent/AP662A/en
Priority to NZ298851A priority patent/NZ298851A/xx
Priority to RO97-01334A priority patent/RO118693B1/ro
Priority to US08/875,173 priority patent/US6107302A/en
Priority to IL11683196A priority patent/IL116831A/en
Priority to HK98101918.0A priority patent/HK1003055B/en
Priority to FI973063A priority patent/FI973063A7/fi
Priority to GEAP19963845A priority patent/GEP20001940B/en
Priority to IS4527A priority patent/IS2268B/is
Priority to OA70051A priority patent/OA10499A/en
Priority to MXPA/A/1997/005462A priority patent/MXPA97005462A/xx
Priority to NO19973326A priority patent/NO315558B1/no
Priority to BG101833A priority patent/BG63393B1/bg
Priority to UY25779A priority patent/UY25779A1/es
Priority to CY0500061A priority patent/CY2531B1/xx
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
GBGB9501178.9A 1995-01-20 1995-01-20 Guanine derivative Pending GB9501178D0 (en)

Priority Applications (42)

Application Number Priority Date Filing Date Title
GBGB9501178.9A GB9501178D0 (en) 1995-01-20 1995-01-20 Guanine derivative
FI973063A FI973063A7 (fi) 1995-01-20 1996-01-19 Guaniinijohdannainen
GEAP19963845A GEP20001940B (en) 1995-01-20 1996-01-19 Valaciclovir Hydrochloride in Essentially Anhydrous Crystalline Form, Processes for its Producing, Use and Method of Treatment
CA002210799A CA2210799C (en) 1995-01-20 1996-01-19 Valaciclovir hydrochloride in anhydrous crystalline form
JP52213196A JP3176633B2 (ja) 1995-01-20 1996-01-19 グアニン誘導体
HR960024A HRP960024B1 (en) 1995-01-20 1996-01-19 Guanine derivative
ZA96449A ZA96449B (en) 1995-01-20 1996-01-19 Guanine derivative
AT96900631T ATE302777T1 (de) 1995-01-20 1996-01-19 Guaninderivat
BR9606768A BR9606768A (pt) 1995-01-20 1996-01-19 Cloridreto de valaciclovir uso do mesmo e processo para o tratamento de infecção virótica de herpes em um ser humano e para a produção de cloridreto de valaciclovir na forma cristalina anidra
UA97084268A UA46001C2 (uk) 1995-01-20 1996-01-19 Кристалічний гідрохлорид валацикловіру (варіанти), спосіб одержання кристалічного валацикловіру та спосіб лікування людини від інфекційного захворювання, спричиненого вірусом герпесу
SK965-97A SK285329B6 (sk) 1995-01-20 1996-01-19 Kryštalický hydrochlorid valacyklovíru, spôsob jeho výroby a jeho použitie
AU44539/96A AU702794B2 (en) 1995-01-20 1996-01-19 Guanine derivative
SI9630717T SI0804436T1 (sl) 1995-01-20 1996-01-19 Derivat gvanina
HU9801836A HU222993B1 (hu) 1995-01-20 1996-01-19 Guaninszármazékok és eljárás ezek előállítására
ES96900631T ES2248806T3 (es) 1995-01-20 1996-01-19 Derivado de la guanina.
IN102MA1996 IN182468B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1995-01-20 1996-01-19
CZ0229497A CZ297065B6 (cs) 1995-01-20 1996-01-19 Hydrochlorid valacykloviru v bezvodé krystalické forme a zpusob jeho výroby
TR97/00656T TR199700656T1 (xx) 1995-01-20 1996-01-19 Guanin derivatlar�.
YU3396A RS49518B (sr) 1995-01-20 1996-01-19 Bezvodni kristalni valaciklovir i postupak za njegovo pripremanje
EE9700175A EE03528B1 (et) 1995-01-20 1996-01-19 Valatsükloviirvesinikkloriid, selle valmistamismeetod ja kasutamine
DK96900631T DK0804436T3 (da) 1995-01-20 1996-01-19 Guaninderivat
ARP960101082A AR002270A1 (es) 1995-01-20 1996-01-19 Clorhidrato de valaciclovir 2-[(2-amino-1,6-dihidro-6-oxo-9h-purin-9-il)metoxi]etil-l-valinato, uso para preparar un medicamento y proceso para obtener dicha forma cristalina
PCT/GB1996/000117 WO1996022291A1 (en) 1995-01-20 1996-01-19 Guanine derivative
PL96321326A PL182175B1 (pl) 1995-01-20 1996-01-19 Chlorowodorek walacyklowiru i sposób wytwarzania chlorowodorku walacyklowiru PL PL PL PL PL PL PL PL PL PL
CN96192662A CN1049893C (zh) 1995-01-20 1996-01-19 缬无环鸟苷盐酸盐及其制法和其制药应用
EA199700124A EA000364B1 (ru) 1995-01-20 1996-01-19 Производные гуанина
KR1019970704916A KR100376074B1 (ko) 1995-01-20 1996-01-19 구아닌유도체
EP96900631A EP0804436B1 (en) 1995-01-20 1996-01-19 Guanine derivative
DE69635106T DE69635106T2 (de) 1995-01-20 1996-01-19 Guaninderivat
APAP/P/1997/001058A AP662A (en) 1995-01-20 1996-01-19 Anhydrous crystalline valaciclovir hydrochloride.
NZ298851A NZ298851A (en) 1995-01-20 1996-01-19 Valiciclovir hydrochloride in anhydrous crystalline form
RO97-01334A RO118693B1 (ro) 1995-01-20 1996-01-19 Clorhidrat de valaciclovir, procedeu de obtinere si metoda de tratament
US08/875,173 US6107302A (en) 1995-01-20 1996-01-19 Guanine derivative
IL11683196A IL116831A (en) 1995-01-20 1996-01-19 Anhydrous crystalline valaciclovir hydrochloride and its preparation
HK98101918.0A HK1003055B (en) 1995-01-20 1996-01-19 Guanine derivative
IS4527A IS2268B (is) 1995-01-20 1997-07-15 Gúanín afleiður
OA70051A OA10499A (en) 1995-01-20 1997-07-16 Guanine derivative
MXPA/A/1997/005462A MXPA97005462A (en) 1995-01-20 1997-07-18 Derived from guan
NO19973326A NO315558B1 (no) 1995-01-20 1997-07-18 Vannfri krystallinsk form av valaciclovir-hydroklorid
BG101833A BG63393B1 (bg) 1995-01-20 1997-08-14 Гуаниново производно
UY25779A UY25779A1 (es) 1995-01-20 1999-10-29 Procedimiento para la preparación de una forma anhidra de clorhidrato de valaciclovir
CY0500061A CY2531B1 (en) 1995-01-20 2005-11-16 Guanine derivative

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9501178.9A GB9501178D0 (en) 1995-01-20 1995-01-20 Guanine derivative

Publications (1)

Publication Number Publication Date
GB9501178D0 true GB9501178D0 (en) 1995-03-08

Family

ID=10768347

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9501178.9A Pending GB9501178D0 (en) 1995-01-20 1995-01-20 Guanine derivative

Country Status (40)

Country Link
US (1) US6107302A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0804436B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP3176633B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100376074B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1049893C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AP (1) AP662A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR002270A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE302777T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU702794B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BG (1) BG63393B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR9606768A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2210799C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (1) CY2531B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ297065B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69635106T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0804436T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA000364B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EE (1) EE03528B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2248806T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI973063A7 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB9501178D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GE (1) GEP20001940B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP960024B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU222993B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL116831A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN182468B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IS (1) IS2268B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO315558B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ298851A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
OA (1) OA10499A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL182175B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RO (1) RO118693B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RS (1) RS49518B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI0804436T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK285329B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TR (1) TR199700656T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA46001C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UY (1) UY25779A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1996022291A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA96449B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
ES2210490T3 (es) * 1996-01-19 2004-07-01 Glaxo Group Limited Uso de valaciclovir para la fabricacion de un medicamento para el tratamiento del herpes genital por una unica administracion diaria.
IT1283447B1 (it) * 1996-07-18 1998-04-21 Ind Chimica Srl Processo di preparazione del valaciclovir e relativi intermedi
EP0976750A4 (en) * 1997-01-17 2001-05-30 Ajinomoto Kk NEW Z-VALACYCLOVIR CRYSTALS
GB0010446D0 (en) * 2000-04-28 2000-06-14 Glaxo Wellcome Kk Pharmaceutical formulation
PT2298769E (pt) * 2001-02-24 2013-11-29 Boehringer Ingelheim Pharma Derivados de xantina, sua preparação e sua utilização como produto farmacêutico
KR100774271B1 (ko) * 2001-09-07 2007-11-08 테바 파마슈티컬 인더스트리즈 리미티드 발라사이클로비르 염산염의 결정질 형태
US20040197396A1 (en) * 2001-11-05 2004-10-07 Fain Helen S Anhydrous crystal form of valaciclovir hydrochloride
MX242714B (es) * 2001-11-14 2006-12-15 Teva Pharma Sintesis y purificacion de valaciclovir.
WO2004000265A2 (en) * 2002-06-24 2003-12-31 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
EP1551838B1 (en) * 2002-10-16 2006-08-09 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
US20060229322A1 (en) * 2002-12-09 2006-10-12 Pau Cid Anhydrous crystalline form of valacyclovir hydrochloride
EP1633753A1 (en) * 2003-05-30 2006-03-15 EOS Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ti Caret A.S. Novel crystalline forms of valacyclovir hydrochloride
EP2014660A3 (en) 2003-06-02 2009-07-15 Teva Pharmaceutical Industries Ltd Novel crystalline forms of valacyclovir hydrochloride
JP2007522130A (ja) * 2004-01-21 2007-08-09 テバ ファーマシューティカル インダストリーズ リミティド 塩酸バラシクロビルの調製方法
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
CA2572268A1 (en) * 2004-06-30 2006-02-02 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US20060178512A1 (en) * 2005-02-04 2006-08-10 Cheruthur Govindan Method for preparing amino acid esters of nucleoside analogues
EP1891071B1 (en) * 2005-05-25 2012-02-22 Eli Lilly And Company Cyclopropanecarboxylate esters of acyclovir
EP1746098A1 (en) * 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20070112193A1 (en) * 2005-11-14 2007-05-17 Khunt Mayur D Valacyclovir process
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
BRPI0711558A2 (pt) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polimorfos
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
CN1903854B (zh) * 2006-08-09 2012-05-23 丽珠医药集团股份有限公司 一种合成盐酸伐昔洛韦的方法
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
US20080281099A1 (en) * 2007-05-07 2008-11-13 Mayur Devjibhai Khunt Process for purifying valacyclovir hydrochloride and intermediates thereof
GB0710277D0 (en) * 2007-05-30 2007-07-11 Univ Birmingham Use of antivirals in the treatment of medical disorders
EP3542801A1 (en) * 2007-08-17 2019-09-25 Boehringer Ingelheim International GmbH Purin derivatives for use in the treatment of fap-related diseases
WO2009031576A1 (ja) * 2007-09-03 2009-03-12 Ajinomoto Co., Inc. バラシクロビル塩酸塩結晶の製造方法
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
PE20140960A1 (es) * 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
AU2009281122C1 (en) * 2008-08-15 2016-04-21 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
WO2010029089A2 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AU2009331471B2 (en) 2008-12-23 2015-09-03 Boehringer Ingelheim International Gmbh Salt forms of organic compound
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
AU2010323068B2 (en) 2009-11-27 2015-09-03 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
JP6034781B2 (ja) 2010-05-05 2016-11-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 併用療法
WO2011158252A1 (en) 2010-06-15 2011-12-22 Matrix Laboratories Ltd Process for the preparation of valacyclovir hydrochloride polymorphic form ii
PH12012502524A1 (en) 2010-06-24 2014-02-10 Boehringer Ingelheim Int Diabetes therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
CN102584825B (zh) * 2011-01-17 2014-04-02 四川科伦药物研究有限公司 一种合成盐酸伐昔洛韦的方法
HUE061596T2 (hu) 2011-07-15 2023-07-28 Boehringer Ingelheim Int Szubsztituált dimer kinazolin származék, annak elõállítása és alkalmazása az I. és II. típusú cukorbetegség kezelésére szolgáló gyógyszerkészítményekben
WO2013076688A1 (en) * 2011-11-25 2013-05-30 Piramal Enterprises Limited A process for the preparation of valacyclovir hydrochloride
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition
CN110437231B (zh) * 2019-09-04 2022-04-29 上药康丽（常州）药业有限公司 一种盐酸伐昔洛韦无水晶型ⅰ的制备方法
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP160A (en) * 1987-08-15 1991-11-18 The Wellcome Foundation Ltd Therapeutic acyclic nucleosides.
ES2157259T3 (es) * 1993-06-10 2001-08-16 Rolabo Sl Procedimiento para preparar esteres de aminoacidos y analogos de nucleosidos.
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative

Also Published As

Publication number Publication date
FI973063A0 (fi) 1997-07-18
AR002270A1 (es) 1998-03-11
ZA96449B (en) 1996-08-07
YU3396A (sh) 1998-12-23
CN1179159A (zh) 1998-04-15
AU4453996A (en) 1996-08-07
SK96597A3 (en) 1998-02-04
KR100376074B1 (ko) 2003-06-02
GEP20001940B (en) 2000-02-05
EE9700175A (et) 1998-02-16
CZ229497A3 (en) 1997-12-17
EA000364B1 (ru) 1999-06-24
CA2210799A1 (en) 1996-07-25
HRP960024B1 (en) 2005-08-31
OA10499A (en) 2002-04-10
DK0804436T3 (da) 2005-12-27
IL116831A0 (en) 1996-05-14
IS4527A (is) 1997-07-15
IS2268B (is) 2007-07-15
EP0804436B1 (en) 2005-08-24
UA46001C2 (uk) 2002-05-15
MX9705462A (es) 1997-10-31
AU702794B2 (en) 1999-03-04
NO973326L (no) 1997-09-16
CY2531B1 (en) 2006-04-12
IL116831A (en) 1998-10-30
PL182175B1 (pl) 2001-11-30
NZ298851A (en) 1999-01-28
BG101833A (bg) 1998-04-30
AP662A (en) 1998-08-19
JPH11503718A (ja) 1999-03-30
NO315558B1 (no) 2003-09-22
JP3176633B2 (ja) 2001-06-18
CZ297065B6 (cs) 2006-08-16
HU222993B1 (hu) 2004-01-28
DE69635106T2 (de) 2006-06-08
EP0804436A1 (en) 1997-11-05
HRP960024A2 (en) 1997-10-31
NO973326D0 (no) 1997-07-18
SK285329B6 (sk) 2006-11-03
EE03528B1 (et) 2001-10-15
KR19980701525A (ko) 1998-05-15
SI0804436T1 (sl) 2006-02-28
BR9606768A (pt) 1997-12-30
FI973063L (fi) 1997-09-18
BG63393B1 (bg) 2001-12-29
CN1049893C (zh) 2000-03-01
CA2210799C (en) 2008-06-10
WO1996022291A1 (en) 1996-07-25
IN182468B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1999-04-17
FI973063A7 (fi) 1997-09-18
UY25779A1 (es) 2000-08-21
TR199700656T1 (xx) 1998-03-21
ES2248806T3 (es) 2006-03-16
RS49518B (sr) 2006-10-27
HUP9801836A2 (hu) 1999-05-28
AP9701058A0 (en) 1997-10-31
ATE302777T1 (de) 2005-09-15
PL321326A1 (en) 1997-12-08
US6107302A (en) 2000-08-22
RO118693B1 (ro) 2003-09-30
DE69635106D1 (de) 2005-09-29
HUP9801836A3 (en) 1999-06-28
EA199700124A1 (ru) 1997-12-30

Similar Documents

Publication Publication Date Title
CY2531B1 (en) Guanine derivative
GB9508565D0 (en) Quiazoline derivative
NZ305444A (en) 4-anilino-7-alkoxy-quinazoline derivatives
IL152383A0 (en) 5-amino-3-cyano-4-ethylsulfinyl-1- phenyl-pyrazole derivatives
IL135376A0 (en) Hydroxyalkyl-phenyl derivatives
GB2306473A8 (en) Glucoxide derivatives
ZA96228B (en) Indolepiperidine derivatives
SG64953A1 (en) Purin-6-one derivatives
HU9600876D0 (en) Benzonitril- and -fluoride derivatives
HUP9600107A3 (en) 9-substituted-2-(2-n-alkoxy-phenyl)-purin-6-one derivatives
NZ332395A (en) Benzonthiazole derivatives
SI0758644T1 (en) Sulfonyl- or sulfinyl-benzoyl-guanidine derivatives
HUP9900672A3 (en) Pyrroloazepine derivatives
SG60005A1 (en) 1-Fluorocyclohexene-difluorophenyl derivatives
IL123621A0 (en) Diarylalkenylamine derivatives
GR3035577T3 (en) Benzisothiazolyl-substituted aminomethylchroman derivatives
ZA964470B (en) Cycloalkane-benzylidene derivatives
IL117858A0 (en) 4-Indolypiperazinyl derivatives
GR3036572T3 (en) 4-amino-benzoylguanidine derivatives
HU9602324D0 (en) Piperidinyl-methyl-oxazolidinon derivatives
EP0754668A3 (de) Fluorbenzylether-Derivate
IL123000A0 (en) Aza-anthracyclinone derivatives
ZA967204B (en) Alkenyl-benzoylguanidine derivatives
ZA96701B (en) 4-Mercaptobenzoylgaunidine derivatives
EP0804205A4 (en) 4-AZA-19-NORANDROSTANDERIVATE